Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP has announced a securities class action lawsuit against ImmunityBio, Inc. (IBRX). Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, are encouraged to contact the firm, with a lead plaintiff deadline set for May 26, 2026. The lawsuit alleges that ImmunityBio’s Executive Chairman, Patrick Soon-Shiong, misrepresented the capabilities of their bladder cancer drug Anktiva, leading to a significant stock drop after a U.S. FDA warning letter cited misleading promotional claims.